Navigation Links
AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Date:12/18/2009

QUEBEC CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH. Termination of the agreement will be effective January 9, 2010.

Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the prostate which, as announced by the Company last week, did not meet its primary endpoint.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "The termination of our agreement with sanofi-aventis U.S. was expected in light of last week's announcement. Our clinical development efforts will now be focused on the following late-stage compounds: in oncology, Keryx, our partner and licensee in North America, has just initiated a Phase 3 trial in multiple myeloma with perifosine, our oral PI3K/Akt inhibitor compound. We are also currently evaluating further development plans for AEZS-108, our targeted doxorubicin conjugate, after recent positive Phase 2 results in ovarian and endometrial cancer. In endocrinology, we are in the process of reactivating a Phase 3 trial with our oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on oncology and endocrine therapy, with proven expertise in drug discovery, development and commerc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
2. AEterna Zentaris Announces Appointment of New Board Member
3. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
6. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
7. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
8. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
9. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
10. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
11. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 PRC Clinical, ... the San Francisco Bay Area, will exhibit and present ... Conference 2015 on March 25th and 26th in ... build relationships with Israeli life science companies seeking to ... The company’s services span all phases of human trials, ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced the ... August of last year. As part of the acquisition, ... Koo continuing his role as CEO for the ... Vegalab S.A., will work alongside Koo and oversee developments ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin ...
(Date:3/4/2015)... 2015   ... und Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte ... Philips (NYSE: PHG, AEX: PHIA) gab heute ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird das ...
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... SHANGHAI , July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, ... of probiotics products in China , today provides,further updates on the ... , ... ended at June,30, 2010 and the total number of bulk ...
... ... losses would come when sorghum, sugar cane and other crops are considered , ... (PRWEB) July 7, 2010 -- Banning ... alone, according to University of Chicago economist Don L. Coursey, Ph.D . , , ...
... announces that a new market research report is available in its catalogue: , ... Building Biotech Technology Transfer Opportunities: Sponsor ... , , ... Drug developers have ...
Cached Biology Technology:China-Biotics Provides Further Updates on Qingpu New Facility 2China-Biotics Provides Further Updates on Qingpu New Facility 3Loss of Atrazine Would Wipe Out 21,000 to 48,000 Jobs Dependant on Agriculture 2Loss of Atrazine Would Wipe Out 21,000 to 48,000 Jobs Dependant on Agriculture 3Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 2Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 3Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 4Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 5Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 6Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 7Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 8Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 9Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success 10
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... estimate of bat deaths caused by wind turbines concludes that ... in 2012 in the contiguous United States. The estimate, published ... techniques to infer the probable number of bat deaths at ... at 21 locations, correcting for the installed power capacity of ...
... Nov. 7, 2013 UT Southwestern Medical Center researchers ... their susceptibility to inflammatory disease, indicating that the production ... body,s circadian clock. The study published in the ... previously hidden pathway by which the body,s circadian clock ...
... D.C. Nov. 7, 2013 -- Although we don,t often think ... lives, from a billowing breeze that buffets a flag, to ... that sustains our lives. One of the basest of bodily ... of fluid motion. Later this month, at the ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3The Tao of pee 2